# Pamlectabart tismanitin

Source: https://onco.cc/drugs/pamlectabart-tismanitin/  
OnCo record `pamlectabart-tismanitin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pamlectabart tismanitin is an experimental antibody-drug conjugate with an amanitin payload from Heidelberg Pharma, in phase 2 trials for relapsed or refractory multiple myeloma.

## Summary

Pamlectabart tismanitin (HDP-101, BCMA-ATAC) is an antibody-drug conjugate with an amanitin payload (ATAC) from Heidelberg Pharma, with Hangzhou Zhongmei Huadong Pharmaceutical as partner. An antibody-drug conjugate in which a BCMA antibody delivers the toxin amanitin to myeloma cells. Its furthest stage is phase 2, for relapsed or refractory multiple myeloma. ClinicalTrials.gov registers it in 2 studies linked below. Phase I part completed early April 2026; phase IIa dose expansion started (company page). FDA Fast Track Oct 2025, orphan designation March 2024. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: HDP-101; BCMA-ATAC
- Tags: pipeline; ctgov-ingest
- Code: HDP-101
- Modality: Antibody-drug conjugate with an amanitin payload (ATAC)
- Mechanism: An antibody-drug conjugate in which a BCMA antibody delivers the toxin amanitin to myeloma cells.

## Sources

- Heidelberg Pharma: heidelberg-pharma.com: https://heidelberg-pharma.com/en/research-development/atac-r-projects
- Heidelberg Pharma: heidelberg-pharma.com: https://heidelberg-pharma.com/en/research-development/atac-r-projects
- Heidelberg Pharma: heidelberg-pharma.com: https://heidelberg-pharma.com/en/research-development/atac-r-projects
- Heidelberg Pharma: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07529782
- ClinicalTrials.gov: trials of HDP-101: https://clinicaltrials.gov/search?intr=HDP-101

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [Heidelberg Pharma](https://onco.cc/companies/heidelberg-pharma/)
- trials: [Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07529782/), [Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma](https://onco.cc/trials/nct04879043/)

---
JSON: https://onco.cc/api/v1/entities/pamlectabart-tismanitin.json